Darapladib , as compared with placebo , reduced the rate of major coronary events ( 9.3 % vs. 10.3 % ; hazard ratio , 0.90 ; 95 % CI , 0.82 to 1.00 ; P = 0.045 ) and total coronary events ( 14.6 % vs. 16.1 % ; hazard ratio , 0.91 ; 95 % CI , 0.84 to 0.98 ; P = 0.02 ) .